1.
A medicine composition for facilitating treating organs of a mammal,
the medicine composition comprising: carbanions, wherein a carbanion
of the carbanions comprises a carbon atom, wherein the carbon atom
comprises a formal charge of -1; and a diluting agent, wherein the
diluting agent is capable of combining with the carbanions for
forming at least one appliable form of the medicine composition,
wherein a ratio of the diluting agent to the carbanions by volume
ranges from 512:1 to 32:1, wherein the combining facilitates applying
of the at least one appliable form of the medicine composition to at
least one organ of the mammal.
2. The medicine composition of
claim 1, wherein the ratio of the diluting agent to the carbanions by
the volume is 284:1.
3. The medicine composition of claim 1,
wherein the ratio of the diluting agent to the carbanions by the
volume is 189:1.
4. The medicine composition of claim 1,
wherein the ratio of the diluting agent to the carbanions by the
volume is 57:1.
5. The medicine composition of claim 1
further comprising an elemental composition in a ratio to the
carbanions by volume, wherein the ratio of the elemental composition
to the carbanions by the volume is 1:9.
6. The medicine
composition of claim 5, wherein the elemental composition comprises
oxygen, hydrogen, nitrogen, phosphorus, potassium, calcium,
magnesium, sulfur, iron, silicon, aluminum, chlorine, and manganese.
7. The medicine composition of claim 1, wherein each
carbanion of the carbanions is capable of creating an
electromechanical reaction with an organic material of at least one
organism present on the at least one organ of the mammal based on the
applying of the at least one appliable form of the medicine
composition, wherein the creating of the electromechanical reaction
disassembles the organic material of the at least one organism for
eliminating the at least one organism, wherein the eliminating of the
at least one organism facilitates the treating of the at least one
organ of the mammal.
8. The medicine composition of claim 1,
wherein the carbanions are derived from at least one organic
material, wherein the at least one organic material is associated
with at least one part of at least one plant, wherein the at least
one plant comprises a corn plant, wherein the at least one part of
the corn plant comprises a leaf, a stem, a grain, a root, and a cob.
9. The medicine composition of claim 1, wherein the diluting
agent comprises at least one cream, wherein the at least one cream
comprises a shea butter.
10. The medicine composition of
claim 1, wherein the diluting agent comprises at least one
moisturizing element.
11. A method for facilitating treating
organs of a mammal using a medicine composition, the method
comprising: transforming, using at least one application device, the
medicine composition into at least one appliable form, wherein the
medicine composition comprises carbanions and a diluting agent,
wherein a carbanion of the carbanions comprises a carbon atom,
wherein the carbon atom comprises a formal charge of -1, wherein the
diluting agent is capable of combining with the carbanions for
forming the at least one appliable form of the medicine composition,
wherein a ratio of the diluting agent to the carbanions by volume
ranges from 512:1 to 32:1; and applying, using the at least one
application device, at least one dosage of the at least one appliable
form of the medicine composition on at least one organ of the mammal
based on the transforming, wherein the applying of the at least one
dosage of the at least one appliable form of the medicine composition
facilitates the treating of the at least one organ of the mammal.
12. The method of claim 11, wherein the at least one
application device comprises a nebulizer, wherein the at least one
organ comprises at least one lung, wherein the at least one appliable
form of the medicine composition comprises an aerosol, wherein the
transforming comprises aerosolizing the medicine composition into the
aerosol, wherein the applying comprises delivering the aerosol to the
at least one lung of the mammal.
13. The method of claim 11,
wherein the at least one application device comprises an emulsifier,
wherein the at least one organ comprises skin, wherein the at least
one appliable form of the medicine composition comprises an emulsion,
wherein the transforming comprises emulsifying the medicine
composition into the emulsion, wherein the applying comprises
covering the skin of the mammal with the emulsion.
14. The
method of claim 11 further comprising generating, using the at least
one application device, the at least one dosage of the at least one
appliable form of the medicine composition, wherein the applying of
the at least one dosage of the at least one appliable form of the
medicine composition is further based on the generating of the at
least one dosage.
15. The method of claim 11, wherein the at
least one dosage of the at least one appliable form of the medicine
composition comprises one ounce of water and at least three drops of
the carbanions, wherein the diluting agent comprises the water.
16.
The method of claim 11, wherein the treating of the at least one
organ comprises eliminating at least one organism from the at least
one organ causing at least one disease in the at least one organ of
the mammal based on the applying, wherein the eliminating comprises
disassembling an organic material of the at least one organism based
on an interaction of the carbanions with the organic material based
on the applying.
17. The method of claim 11, wherein the
treating of the at least one organ comprises regenerating at least
one tissue of the at least one organ of the mammal based on the
applying.
18. The method of claim 11, wherein the at least
one dosage of the at least one appliable form of the medicine
composition is associated with a dosing frequency, wherein the dosing
frequency comprises three times a day for at least one three days,
wherein the applying of the at least one dosage of the at least one
appliable form of the medicine composition with the dosing frequency
facilitates the treating of the at least one organ.
19. The
method of claim 11, wherein the applying of the at least one
appliable form of the medicine composition is associated with an
applying duration, wherein the treating of the at least one organ is
based on the applying of the at least one appliable form of the
medicine composition for the applying duration.
20. The
method of claim 11, wherein the at least one appliable form of the
medicine composition comprises a solution, wherein the solution is
appliable to the at least one organ using at least one application
method, wherein the applying of the solution of the medicine
composition to the at least one organ facilitates the treating of the
at least one organ.
Description
FIELD OF THE INVENTION
Generally, the present
disclosure relates to the field of Drug, bio-affecting, and body
treating compositions. More specifically, the present disclosure
relates to a medicine composition for facilitating treating organs of
a mammal.
BACKGROUND OF THE INVENTION
When it comes
to treatment for diseases caused by organisms such as viruses
bacteria, fungi, insects, it may be a financial issue for people who
are in need of treatment. Further, the organism such as the viruses,
the bacterial, fungi, insects, etc. may infect organs of mammal such
as humans causing the diseases. Further, treatments for infectious
viruses causing the diseases may vary in price. For the very common
and well-known virus, the materials needed to produce a treatment for
the said virus will most likely be relatively cheap. On the other
hand, for the more rare and undiscovered virus, the materials needed
to produce a treatment for the said virus will definitely be
expensive as there are lesser known cases of the rare virus, and
maybe more difficult to find a treatment. Another issue with
infectious viruses is that not all of the viruses have been studied
as there is an unknown number of undiscovered viruses. One prime
example of an unknown virus was COVID-19. In December 2019, COVID-19
was newly discovered as an outbreak occurred from Wuhan, China.
COVID-19 lead to an international pandemic. Due to the unknown virus
COVID-19, the treatment for COVID-19 has yet been discovered even a
few months after the discovery of the virus itself. The complexity of
finding and producing a treatment for COVID-19 is extremely difficult
due to the anomaly of the newly discovered virus.
Existing
compositions for facilitating treating organs of a mammal are
deficient with regard to several aspects. For instance, existing
compositions do not perform treatment of various organs of a mammal.
Furthermore, existing compositions do not eliminate viruses,
bacteria, fungi, and insects present on various organs for treating
the various organs. Moreover, existing compositions do not totally
derive from organic matter.
Therefore, there is a need for an
improved medicine composition for facilitating treating organs of a
mammal that may overcome one or more of the above-mentioned problems
and/or limitations.
SUMMARY OF THE INVENTION
This
summary is provided to introduce a selection of concepts in a
simplified form, that are further described below in the Detailed
Description. This summary is not intended to identify key features or
essential features of the claimed subject matter. Nor is this summary
intended to be used to limit the claimed subject matter's scope.
Disclosed herein is a medicine composition for facilitating
treating organs of a mammal, in accordance with some embodiments.
Accordingly, the medicine composition may include carbanions and a
diluting agent. Further, a carbanion of the carbanions may include a
carbon atom. Further, the carbon atom may include a formal charge of
-1. Further, the diluting agent may be capable of combining with the
carbanions for forming at least one appliable form of the medicine
composition. Further, a ratio of the diluting agent to the carbanions
by volume ranges from 512:1 to 32:1. Further, the combining
facilitates applying of the at least one appliable form of the
medicine composition to at least one organ of the mammal.
Further
disclosed herein is a method for facilitating treating organs of a
mammal using a medicine composition, in accordance with some
embodiments. Accordingly, the method may include a step of
transforming, using at least one application device, the medicine
composition into at least one appliable form. Further, the medicine
composition may include carbanions and a diluting agent. Further, a
carbanion of the carbanions may include a carbon atom. Further, the
carbon atom may include a formal charge of -1. Further, the diluting
agent may be capable of combining with the carbanions for forming the
at least one appliable form of the medicine composition. Further, a
ratio of the diluting agent to the carbanions by volume ranges from
512:1 to 32:1. Further, the method may include a step of applying,
using the at least one application device, at least one dosage of the
at least one appliable form of the medicine composition on at least
one organ of the mammal based on the transforming. Further, the
applying of the at least one dosage of the at least one appliable
form of the medicine composition facilitates the treating of the at
least one organ of the mammal.
Both the foregoing summary and
the following detailed description provide examples and are
explanatory only. Accordingly, the foregoing summary and the
following detailed description should not be considered to be
restrictive. Further, features or variations may be provided in
addition to those set forth herein. For example, embodiments may be
directed to various feature combinations and sub-combinations
described in the detailed description.
BRIEF DESCRIPTION OF
THE DRAWINGS
The accompanying drawings, which are
incorporated in and constitute a part of this disclosure, illustrate
various embodiments of the present disclosure. The drawings contain
representations of various trademarks and copyrights owned by the
Applicants. In addition, the drawings may contain other marks owned
by third parties and are being used for illustrative purposes only.
All rights to various trademarks and copyrights represented herein,
except those belonging to their respective owners, are vested in and
the property of the applicants. The applicants retain and reserve all
rights in their trademarks and copyrights included herein, and grant
permission to reproduce the material only in connection with
reproduction of the granted patent and for no other purpose.
Furthermore, the drawings may contain text or captions that
may explain certain embodiments of the present disclosure. This text
is included for illustrative, non-limiting, explanatory purposes of
certain embodiments detailed in the present disclosure.
FIG.
1 is a table listing ingredients of a medicine composition for
facilitating treating organs of a mammal, in accordance with some
embodiments.
FIG. 2 is a flowchart of a method for
facilitating treating organs of a mammal using a medicine
composition, in accordance with some embodiments.
FIG. 3 is
an illustration of carbanions of the medicine composition, in
accordance with some embodiments.
FIG. 4 is a front view of a
container containing the medicine composition, in accordance with
some embodiments.
FIG. 5 is a plot of light scattering by the
carbanions through a dynamic light scattering, in accordance with
some embodiments.
FIG. 6 is a magnified view of a sample of a
solution of the medicine composition, in accordance with some
embodiments.
FIG. 7 is a magnified view of a sample of the
solution, in accordance with some embodiments.
FIG. 8 is a
magnified view of a sample of a solution of the medicine composition,
in accordance with some embodiments.
FIG. 9 is a magnified
view of a sample of the solution, in accordance with some
embodiments.
FIG. 10 is a magnified view of a sample of a
solution of the medicine composition, in accordance with some
embodiments.
FIG. 11 is a schematic of a carbanion of the
carbanions, in accordance with some embodiments.
FIG. 12 is
an illustration of gram-positive bacteria.
FIG. 13 is an
illustration of gram-negative bacteria.
FIG. 14 is an
illustration of an effect of NG 1 on Alternaria alternata, in
accordance with some embodiments.
FIG. 15 is an illustration
of an effect of NG 2 on Sclerotium rolfsii, in accordance with some
embodiments.
FIG. 16 is an illustration of an effect of NG 1
on Macrophomina phaseolina, in accordance with some embodiments.
FIG. 17 is a table of an initial screen of pathogens vs.
dilution of Formula S-101, in accordance with some embodiments.
FIG. 18 is a table of a second screen of pathogens vs.
dilution of Formula S-101, in accordance with some embodiments.
FIG. 19 is a table of the second screen of pathogens vs.
dilution of Formula S-101, in accordance with some embodiments.
FIG. 20 is a table of a subset of the second screen of
pathogens vs. dilutions of Formula S-101, in accordance with some
embodiments.
FIG. 21 is a table of therapeutic options for
fungal lung infections.
FIG. 22 is a table of antifungal
treatment options.
FIG. 23 is a flow diagram of a method of
facilitating producing the medicine composition for treating diseases
using the medicine composition, in accordance with some embodiments.
FIG. 24 is a flow diagram of the method of facilitating
producing the medicine composition for treating the diseases using
the medicine composition, in accordance with some embodiments.
FIG.
25 is a flow diagram of the mining stage of the method, in accordance
with some embodiments.
FIG. 26 is a flow diagram of the
mixture stage of the method, in accordance with some embodiments.
FIG. 27 is a flow diagram of the production stage of the
method, in accordance with some embodiments.
FIG. 28 is a
flow diagram of the treatment stage of the method, in accordance with
some embodiments.
FIG. 29 is a table of compositional
elements of the medicine composition, in accordance with some
embodiments.
FIG. 30 is a chart of the lab results of the
medicine composition, in accordance with some embodiments.
FIG.
31 is a table of compositional elements of the medicine composition,
in accordance with some embodiments.
DETAIL DESCRIPTIONS OF
THE INVENTION
As a preliminary matter, it will readily be
understood by one having ordinary skill in the relevant art that the
present disclosure has broad utility and application. As should be
understood, any embodiment may incorporate only one or a plurality of
the above-disclosed aspects of the disclosure and may further
incorporate only one or a plurality of the above-disclosed features.
Furthermore, any embodiment discussed and identified as being
"preferred" is considered to be part of a best mode
contemplated for carrying out the embodiments of the present
disclosure. Other embodiments also may be discussed for additional
illustrative purposes in providing a full and enabling disclosure.
Moreover, many embodiments, such as adaptations, variations,
modifications, and equivalent arrangements, will be implicitly
disclosed by the embodiments described herein and fall within the
scope of the present disclosure.
Accordingly, while
embodiments are described herein in detail in relation to one or more
embodiments, it is to be understood that this disclosure is
illustrative and exemplary of the present disclosure, and are made
merely for the purposes of providing a full and enabling disclosure.
The detailed disclosure herein of one or more embodiments is not
intended, nor is to be construed, to limit the scope of patent
protection afforded in any claim of a patent issuing here from, which
scope is to be defined by the claims and the equivalents thereof. It
is not intended that the scope of patent protection be defined by
reading into any claim limitation found herein and/or issuing here
from that does not explicitly appear in the claim itself.
Thus,
for example, any sequence(s) and/or temporal order of steps of
various processes or methods that are described herein are
illustrative and not restrictive. Accordingly, it should be
understood that, although steps of various processes or methods may
be shown and described as being in a sequence or temporal order, the
steps of any such processes or methods are not limited to being
carried out in any particular sequence or order, absent an indication
otherwise. Indeed, the steps in such processes or methods generally
may be carried out in various different sequences and orders while
still falling within the scope of the present disclosure.
Accordingly, it is intended that the scope of patent protection is to
be defined by the issued claim(s) rather than the description set
forth herein.
Additionally, it is important to note that each
term used herein refers to that which an ordinary artisan would
understand such term to mean based on the contextual use of such term
herein. To the extent that the meaning of a term used herein--as
understood by the ordinary artisan based on the contextual use of
such term--differs in any way from any particular dictionary
definition of such term, it is intended that the meaning of the term
as understood by the ordinary artisan should prevail.
Furthermore,
it is important to note that, as used herein, "a" and "an"
each generally denotes "at least one," but does not exclude
a plurality unless the contextual use dictates otherwise. When used
herein to join a list of items, "or" denotes "at least
one of the items," but does not exclude a plurality of items of
the list. Finally, when used herein to join a list of items, "and"
denotes "all of the items of the list."
The
following detailed description refers to the accompanying drawings.
Wherever possible, the same reference numbers are used in the
drawings and the following description to refer to the same or
similar elements. While many embodiments of the disclosure may be
described, modifications, adaptations, and other implementations are
possible. For example, substitutions, additions, or modifications may
be made to the elements illustrated in the drawings, and the methods
described herein may be modified by substituting, reordering, or
adding stages to the disclosed methods. Accordingly, the following
detailed description does not limit the disclosure. Instead, the
proper scope of the disclosure is defined by the claims found herein
and/or issuing here from. The present disclosure contains headers. It
should be understood that these headers are used as references and
are not to be construed as limiting upon the subjected matter
disclosed under the header.
The present disclosure includes
many aspects and features. Moreover, while many aspects and features
relate to, and are described in the context of a medicine composition
for facilitating treating organs of a mammal, embodiments of the
present disclosure are not limited to use only in this context.
Overview:
The present disclosure describes a medicine
composition for facilitating treating organs of a mammal. Further,
the medicine composition may include carbanions. Further, the
carbanions facilitate the treating of the organs of the mammal.
Further, the present disclosure describes a method for
treating the organs using the medicine composition.
Further,
the present disclosure may provide a treatment of the contagious and
infectious lung bacterial and fungi diseases. Furthermore, the
present disclosure may provide a cheap and cost-efficient treatment
for the contagious and/or infectious lung bacterial, and fungi
diseases. The present disclosure also provides a treatment to cure
multiple known lung bacterial and fungi diseases and potentially
undiscovered lung bacterial and fungi diseases. The present
disclosure may include a mining stage, a mixture stage, a production
stage, and a treatment stage.
Further, the present describes
carbanions for facilitating COVID-19 Treatment, Control of Viruses,
Fungi, Bacteria, and Insect, and Adjuvant & Nebulized Drug
Delivery to Lungs and Skin of the Mammal.
Further, the
carbanions may include individual atoms. Further, the carbanions may
include negatively charged carbon atoms. Further, the negatively
charged carbon atom may include a formal charge of -1. Further, the
negatively charged carbon atoms may be created by making use of the
physical chemistry of carbon atoms. Further, the physical chemistry
may be the study of macroscopic, atomic, subatomic, and particulate
phenomena in chemical systems in terms of the principles, practices,
and concepts of physics such as motion, energy, force, time,
thermodynamics, quantum chemistry, statistical mechanics, analytical
dynamics and chemical equilibrium. Further, the carbanions may be
created by making the use of the physical chemistry of the
carbanions. Further, the physical chemistry may be the study of
macroscopic, atomic, subatomic, and particulate phenomena in chemical
systems in terms of the principles, practices, and concepts of
physics such as motion, energy, force, time, thermodynamics, quantum
chemistry, statistical mechanics, analytical dynamics and chemical
equilibrium. Further, the physical chemistry is the study of how
matter behaves on a molecular and atomic level and how chemical
reactions occur. Based on the analyses, physical chemists may develop
new theories, such as how complex structures are formed. Physical
chemists often work closely with materials scientists to research and
develop potential uses for new materials. Further, the physical
chemistry may be used in observing the assembly of molecules and
determining, measuring, and quantifying the assembly of the
molecules. Further, the physical chemistry may allow for assembling
of molecules in crystals and solutions and observing and measuring of
the arrangements of atoms and molecules and aggregates of the atoms
and the molecules in the solutions as well as in crystals and various
properties the aggregates of surfactants impart to a product.
Further, diffraction, infrared, and microscopy methods are used for
observing the assembly of the molecules and further determining,
measuring, and quantifying the assembly of the molecules. Further,
the physical chemistry may be used for developing better ways to
measure and quantify aspects of the ingredients for developing better
products. Further, physical chemistry provides an understanding of
the physical properties of atoms and molecules, the way chemical
reactions work, and what these properties reveal. Further, the
physical chemistry involves analyzing materials, developing methods
to test and characterize the properties of materials, developing
theories about these properties, and discovering the potential use of
the materials. Using sophisticated instrumentation and equipment has
always been an important aspect of physical chemistry. Most physical
chemistry labs are full of analytical instruments, which may include
lasers, mass spectrometers, nuclear magnetic resonance, and electron
microscopes. Further, the physical chemistry may provide an
understanding of chemical properties and describes the behavior of
chemicals using theories of physics and mathematical computations.
Further, the properties and reactions of the chemicals may be
predicted using the physical chemistry. Physical chemistry describes
fundamental physical characteristics of material be it solid, liquid,
or gas. Further, the physical chemistry may be used for the
development of materials, including plastics, ceramics, catalysis,
electronics, fuel, batteries, surfactants, and colloids, and personal
care products.
Further, the carbanions may include carbon
atoms. Further, the carbon atoms may be associated with CO2 (carbon
dioxide) gas. Further, an average person breathes out around 500
liters of the greenhouse gas CO2, which amounts to around 1 kg or 2.3
pounds of mass. Further, the world's population is around 6.8
billion, collectively breathing out around 2500 million tons of the
CO2, which is around 7 percent of the annual CO2 tonnage churned out
by the burning of fossil fuel around the world. Further, the CO2
breath out by the average person may be a part of a natural cycle, by
which the body of the average person may convert carbohydrates from
CO2-absorbing plants into energy, plus water and CO2. Further, the
average person may breathe the carbon atoms of the CO2 and consume
the carbon atoms of plants.
Further, the carbanions may be
created using pico-technology. Further, the pico-technology is one of
the most promising realms of science, bringing new products to
society in many industries. Further, the pico-technology is only
about particle having size 1000 times smaller than a nanometer. The
product is made mostly of Carbon and Nitrogen and trace elements.
There are 25,400,000 nanometers in one inch. There are 1000 Pico
meters in a nanometer; Therefore an inch has 25,400,000,000 Pico
meters, and a human hair is 80,000,000 to 100,000,000 Pico meters
thick. Further, pico-technology may be described as involving the
alteration of the structure and the chemical properties of individual
atoms through the manipulation of energy states of electrons within
the individual atoms to produce states with unusual properties,
producing some form of exotic atoms. Further, the pico-technology may
allow the usage of atoms singularly. Further, the pico-technology may
be used for the fabrication of structures where atoms may be
positioned with sub-nanometer accuracy. This may be important where
interaction with a single atom or molecule may be desired. Further,
the pico-technology may be used for altering electron distributions
around atoms to promote surface energy to achieve inhibited infection
without potential nanomaterial toxicity concerns. Further, the
pico-technology may be used to describe the control of electron
distribution around the atoms to provide desirable properties.
Further, the control of the electron distribution may greatly change
surface energy and, thus, the way that proteins adsorb onto a
material. Further, the excitement or rearrangement of electrons
around the atoms may influence many cellular functions including cell
movement, intracellular transport to organelles, adhesion, growth,
and ECM formation. Further, the pico-technology may control cellular
microtubules (MTs). MTs are cylindrical cellular formations 25 nm in
diameter, and they are made out of tubulins. Dynamic instability due
to MT plus end-binding proteins also called "plus end-tracking
proteins", are able to "surf" the dynamic ends of the
MTs. Further, when tips are expressed as green fluorescent proteins,
the fluorescence is the brightest at the MT and decreases in
intensity toward the minus end of the MT, forming a comet tail.
Further, external stimulation is used to excite the MT and
end-binding proteins to promote the movement of cells using the
pico-technology. This may be a less toxic manner through which to
alter surface energy to increase tissue growth since electron
distributions may be changed for numerous macro-, micro-, or
nanomaterials. Further, the pico-technology may be used to reduce the
toxicity in any macro-, micro-, or nanomaterials by exciting
electrons. The change in electron distribution, along with the
associated charge redistribution, may alter surface energetics to
change the adsorption of certain proteins (as well as cellular
functions).
Further, the carbanions may be created using
Femto-technology. Further, the Femto-technology may be used for
creating 8-octet, 9-nonet, 10-dectet, 11-undectet, and 12-duodectet
by addition of electron on a carbon atom. Further, the
Femto-technology may be used for matter manipulation for modifying
the carbon atom.
Further, the carbanions may be individual
atoms or atoms in covalent bonds. Further, the individual atoms alone
or the atoms in the covalent bonds may create powerful
electromechanical reactions to disassemble organic material, one atom
per atom at a time. Further, the individual atoms alone or the atoms
in the covalent bond may work on the fungi, the bacteria, or the
viruses to eliminate the fungi, the bacteria, or the viruses.
Further, the individual atoms alone or the atoms in the covalent bond
may eliminate Shingles, Basil Cell Cancer, Squamous Cell Cancer,
Poison Ivy, Oak, Sumac, Diabetic Ulcers, Wounds, Plaque Psoriasis,
Genetic Blistering, Head lice, and Whopping Cough of humans. Further,
the individual atoms alone or the atoms in the covalent bond may
regenerate or grow the skins on the humans.
Further, a Pico
Skin may include the carbanions. Further, the Pico Skin in a 1/512
solution may be used for treating and curing abrasions on skins.
Further, the carbanions may include PicoMed Skin Virus's,
PicoMed Skin Acne Cleans, PicoMed Skin Actinic Keratosis, PicoMed
Skin Alopecia Areata, PicoMed Skin Athlete's Foot, PicoMed Skin
Atopic Dermatitis, PicoMed Skin Atopic Eczema, PicoMed Skin
Bacteria's, PicoMed Skin Barrier function, firmness and elasticity,
PicoMed Skin Beauty Habits, Skin Care, and Makeup, PicoMed Skin Bed
Bugs, PicoMed Skin Biofilms Cleanse, PicoMed Skin Biofilms Flush
Cleanse, PicoMed Skin Birthmarks and Other Skin Pigmentation
Problems, PicoMed Skin Black Seed-like "specks" or "Dots"
from Lesions Cleanse, PicoMed Skin Black Tar-like substance from skin
pores Cleanse, PicoMed Skin Blastomycosis, PicoMed Skin Boils,
PicoMed Skin Bruises, PicoMed Skin Bug Bites and Stings, PicoMed Skin
Burns, PicoMed Skin Cancer, PicoMed Skin Canker Sores Health, PicoMed
Skin Cellulitis, PicoMed Skin Chiggers (Bites), PicoMed Skin
Collembola, PicoMed Skin Conditions, PicoMed Skin Contact Dermatitis,
PicoMed Skin Corns, PicoMed Skin Crust/Scab/Callus like Formations
Cleanse, PicoMed Skin Cuts, Scrapes and Puncture Wounds, PicoMed Skin
Cysts, PicoMed Skin Dark or black specks in your sheets Cleanse,
PicoMed Skin Dark or black specks on your body Cleanse, PicoMed Skin
Dercum's Syndrome, PicoMed Skin Diabetics' Dry Skin Relief
Rehydrating Lotion, PicoMed Skin Diaper Rash, PicoMed Skin Discolored
Cleanse Cleanse, PicoMed Skin Divots in my skin are now flush
Cleanse, PicoMed Skin Dry Skin, PicoMed Skin Eczema Relief Cream,
PicoMed Skin Erythema Nodosum, PicoMed Skin Extremely Dry, Rough,
Callus, PicoMed Skin Fibers Black Cleanse, PicoMed Skin Fibers Blue
Cleanse, PicoMed Skin Fibers Red Cleanse, PicoMed Skin Filaments
Cleanse, PicoMed Skin Fire Ant Bites Infection Prevention, PicoMed
Skin Folliculitis, PicoMed Skin Freckles, PicoMed Skin Frostbite,
PicoMed Skin Fungal Nails, PicoMed Skin Fungals and Molds Cleanse,
PicoMed Skin Fungi's, PicoMed Skin Granulating Tissue hard and
crystal like Cleanse, PicoMed Skin Granules Above/Below Skin Cleanse,
PicoMed Skin Hair Loss, PicoMed Skin Hand Cream moisturizes, PicoMed
Skin Healing Cleanse, PicoMed Skin Heat Rash, PicoMed Skin Hematoma,
PicoMed Skin Herpes Simplex Infections (Non-Genital), PicoMed Skin
Hives, PicoMed Skin Hyperhidrosis, PicoMed Skin Genetic Blistering
Disease, PicoMed Skin Inflammation yes or no Cleanse, PicoMed Skin
Ingrown Hair, PicoMed Skin Ingrown Toenail, PicoMed Skin Intertrigo,
PicoMed Skin Keratin 2006 For Nails, Skin and Hair, PicoMed Skin
Itch, PicoMed Skin Jock Itch, PicoMed Skin Keloid, PicoMed Skin
Keratosis Pilaris, PicoMed Skin Lesions Cleanse, PicoMed Skin
Lesions--Itchy, Sore, Painful, Slow Healing Cleanse, PicoMed Skin
Lesions with Fuzzballs Cleanse, PicoMed Skin Lichen Planus, PicoMed
Skin Lichen Sclerosus, PicoMed Skin Loss Its Elasticity And Sags,
PicoMed Skin Melasma, PicoMed Skin Moisturizing Cream For Diabetis
Skin, PicoMed Skin Moles, PicoMed Skin Molluscum Contagiosum, PicoMed
Skin New Wiry or Thick Hair Over Lesions Before Cleanse, PicoMed Skin
Oozing Cleansev, PicoMed Skin Open Sores, Wounds or Cuts Cleanse,
PicoMed Skin Parasites Cleanse, PicoMed Skin Pigment Changes Cleanse,
PicoMed Skin Pilonidal Cyst, PicoMed Skin Pimples long lasting
Cleanse, PicoMed Skin Pityriasis Rosea, PicoMed Skin Poison Ivy,
PicoMed Skin Poison Oak, PicoMed Skin Postherpetic Neuralgia, PicoMed
Skin Psoriasis, PicoMed Skin Psoriatic Arthritis, PicoMed Skin Rash,
PicoMed Skin Rashes Cleanse, PicoMed Skin Red Cleanse, PicoMed Skin
Rhinoplasty, PicoMed Skin Ringworm, PicoMed Skin Rosacea, PicoMed
Skin Rothmund-Thomson Syndrome, PicoMed Skin Scabbing Cleanse,
PicoMed Skin Scabies, PicoMed Skin Scars, PicoMed Skin Seborrhea,
PicoMed Skin Seborrheic Dermatitis, PicoMed Skin Seed Like specks
Cleanse, PicoMed Skin Sensation Biting Cleanse, PicoMed Skin
Sensation Burning Cleanse, PicoMed Skin Sensation Crawling Cleanse,
PicoMed Skin Sensation Creeping Cleanse, PicoMed Skin Sensation
Itching Cleanse, PicoMed Skin Sensation Pain Cleanse, PicoMed Skin
Sensation Pinching Cleanse, PicoMed Skin Sensation Pricking Cleanse,
PicoMed Skin Sensation Stinging Cleanse, PicoMed Skin Sensation Worms
or wire like structures Cleanse, PicoMed Skin Sensitivity Cleanse,
PicoMed Skin Shards hard and crystal like glass Cleanse, PicoMed Skin
Shingles (Herpes Zoster), PicoMed Skin Shingles and Pregnancy,
PicoMed Skin Spider Bites (Black Widow and Brown Recluse), PicoMed
Skin Spreading Cleanse, PicoMed Skin Stretch Marks, PicoMed Skin
Strongyloides, PicoMed Skin Summer Skin Hazards, PicoMed Skin Sun
Protection and Sunscreens, PicoMed Skin Sun Safety, PicoMed Skin
Sunburn and Sun Poisoning, PicoMed Skin Sun-Sensitive Drugs
(Photosensitivity to Drugs), PicoMed Skin Texture--Leathery,
callus-like developed Cleanse, PicoMed Skin Tinea Versicolor, PicoMed
Skin Tissue granulating and filling Cleanse, PicoMed Skin Venous
Stasis Ulcer, Varicose Ulcers, or Ulcus Cruris, PicoMed Skin
Vitiligo, PicoMed Skin Warts (Common Warts), PicoMed Skin
Weber-Christian Disease, PicoMed Skin Wrinkles, etc.
Further,
the present disclosure describes pico-products comprising the
carbanions. Further, the pico-products may include a PicoMed, a
PicoCare, PicoSkin, etc. Further, the pico-products comprising the
carbanions may have the following characteristics:
1). No
harm to air (no GWC, ODC, VOHAP, or VOC) soil, or water.
2).
cannot be made of organic chemistry, graphene, or nanotechnology,
just single atom Pico technology or physical chemistry
3).
The goals are primary distribution as an OTC product.
4). It
must be made of atomic elements and not molecules.
5). Must
be able to kill all pests, be it bacteria, fungi, viruses, and
insects.
6). Must be able to deep clean and grow skin and
heal wounds just days not weeks
7). Must be able to penetrate
the shields of all pests.
8). Must be approved at the State
and or Federal FDA or better be exempt.
9). Must be safe for
humans, bees, birds, and animals--zero side effects.
10).
Must be made of 100% new organic carbon.
11). No Chemicals
12). No Biologicals
13). No Nanotechnology
14).
No Graphene
15). No Molecules
16). Eliminate Sickness
Further, the pico-products may be formed using the physical
chemistry. Further, the pico-products may 89% Biobased Content.
Further, the pico-products may be used for the elimination of
vital elements in bacteria, insects, fungi, and viruses.
Further,
the pico-products is configured for eliminating the cell membrane of
the bacteria and puncturing the cell membrane. Further, the
eliminating and the puncturing of the cell membrane may drain
proteins and lipids from the bacteria.
Further, the
pico-products is configured for eliminating the cellulose and chitin
of the fungus.
Further, the pico-products is configured for
eliminating strands of a nucleic acid of the virus, either DNA or RNA
of the virus, and protective protein coat of the virus (the capsid),
or a lipid envelope of the virus, surrounding the protein of the
virus.
Further, the pico-products is configured for
dissolving cellular membranes of the insects, eliminating cells
desiccation of the insects, eliminating or penetrating cellular
metabolism of the insects, dissolving cuticles of the insects,
eliminating lubrication joints of the insects leading to paralysis,
stripping the protective shields of the insects, eliminating
exoskeleton structure of the insects, and dissolving chitin and
protein substances of the insects.
Further, the pico-products
immediately impacts the exoskeleton structure of the pest upon
contact by disrupting the molecular structure of the chitin and other
protein substances that protect the insect. This mechanism of action
triggers the rapid and irreversible deterioration of the insect's
spiracles and tracheal system, resulting in suffocation. Further, the
pico-products kills insects with the elimination of chitin. Further,
the chitin is a polysaccharide and a carbohydrate that has a chain of
sugar molecules. Further, chitin has a structure like cellulose.
Additionally, the chitin may be present in the exoskeletons of the
insects.
Further, the pico-products benefit from the
revolutionary method of insect control with an absence of undesirable
side effects on human health and no harm to the ecosystem.
Additionally, unlike standard insecticides in use today, no built-in
resistance may be developed by the targeted insects.
Further,
the pico-products may be mechanical in primary sequential steps.
Further, a first step is a direct interaction between the surface and
the outer membrane of the pests, causing the membrane to rupture and
leak fluids, proteins, and nutrients.
Further, the
pico-products may attack pests at the atom level. Further, at the
atom level, the shield of the pests starts to disassemble. Further,
the pico-products kills the pests by eliminating the shield.
Lastly, in a few more ways, the pico-products'
electromechanical effect may affect the pests: There may be a second
step related to the holes in the outer membrane, through which the
pests lose vital nutrients, protein, water, and components, causing a
general weakening of the pests. Electromechanical effect of the
pico-products may affect pests, the pico-products penetrates and
dissolves lipid of cellular membranes of the pests. This causes cell
desiccation to leak water, proteins, and nutrients and collapse. By
interfering with cellular metabolism during metamorphosis. By
dissolving cuticles, the lubrication in the insect and joints of the
insects, leading to paralysis. By stripping the pests' protective
shields (wax, biofilm, etc.), rendering the pests defenseless against
subsequent treatment. The extracts impact the exoskeleton structure
of the pests upon contact by disrupting the molecular structure of
the chitin and other protein substances that protect the insect. The
extracts may have the ability to penetrate complex hydrocarbon chains
and disintegrate the insects. The change in the environment for
growth with PH from acidophils and neutrophils to alkaliphiles.
Further, the pico-products may be configured for punching
holes in a cell of the pests. Further, the punching of the holes in
the cell breaches a main defense of the cell. Further, an unopposed
stream of the pico-products enters the cell. This puts several vital
processes inside the cell in danger. Further, the pico-products
overwhelm the inside of the cell and obstruct cell metabolism (i.e.,
the biochemical reactions needed for life). Further, the
pico-products bind to enzymes of the cell halting the activity of the
cell. Further, the pests no longer "breathe", "eat",
"digest", "reproduce" or "exist".
Further, an outer membrane of the cell, including that of a
single cell organism like pests, is characterized by a stable
electrical micro-current. This is often called "transmembrane
potential", and is literally, a voltage difference between the
inside and the outside of a cell. It is strongly suspected that when
a pest comes in contact with the pico-products, short-circuiting of
the current in the cell membrane may occur. Further, the current
weakens the outer membrane and creates holes for leaking water,
proteins, and nutrients from the cell.
Further, the
pico-products effects fast and affect such a wide range of pests. The
experiences observed explain the speed with which pests and other
pests perish on pico-products surfaces by the multi-targeted effects.
Further, membrane perforation may inhibit any given enzyme that
"stands in its way," and stops the cell from transporting
or digesting nutrients, repairing its damaged membrane, and breathing
or multiplying. This makes the pest harmless to humans, birds, and
animals. This has no side effects or harm on human, birds, and animal
health. These solutions do not harm mammal cells nor do the solutions
attack the neurological systems of humans, birds, and animals.
Further, the pico-products may lyse cells to extract protein or
organelles, or to permeabilize the membranes of living cells.
The
pico-products dissolves lipids from cell membranes making the cell
membranes permeable to antibodies. Because the organic solvents also
coagulate proteins, the pico-products may be used to fix and
permeabilize cells at the same time. Saponin interacts with membrane
cholesterol, selectively removing it and leaving holes in the
membrane. Permeabilization is the process of making something, such
as a membrane or cell wall, permeable. Lyse is a verb referring to
the process of lysis, the death of a cell. Lysis refers to the
breaking down of the membrane of a cell, often by viral, enzymic, or
osmotic mechanisms that compromise cell integrity. A fluid containing
the contents of lysed cells is called a lysate. In molecular biology,
biochemistry, and cell biology laboratories, cell cultures may be
subjected to lysis in the process of purifying the components, as
protein purification, DNA extraction, RNA extraction, or purifying
organelles.
Trophobiosis Cycle: Pesticides weaken plants.
Weakened plants open the door to pests and disease. Further, the
pesticides precipitate pest attacks and disease susceptibility, and
thus the pesticides induce a cycle of further pesticide use.
Further, the pico-products may include a PicoMed. Further,
the PicoMed may be made of only atoms 1000 times smaller than
nanometer and made of Femto-technology (Electrons, Protons, Neutrons)
elements.
Further, the present disclosure describes a
composition comprising carbanions. Further, the carbanions are
created using picotechnology. Further, the picotechnology works atom
to atom for mechanical disassembly of Virus, Bacteria, Insect, and
Fungi control. Further, a single drop of the composition may include
5 sextillion charged atoms. Further, the charged atoms restrict
viruses' elemental mode of action by eliminating strands of nucleic
acid, either DNA or RNA, and a protective protein coat (the capsid),
or a lipid envelope, surrounding the protein of the viruses.
Further, the present disclosure describes a composition
comprising carbanions for treating lung cancer. Further, a dosage of
3 drops of PicoMed given using a nebulizer for 5 consecutive days
includes 75 sextillion carbanions for treating the lung cancer.
Further, the present disclosure describes a method and a
process of creating carbanions that are used as a treatment for
contagious and/or infectious viruses are shown. The method and
process may include four stages. The process comprises a mining
stage, a mixture stage, a production stage, and a treatment stage.
The four different stages define the method and process of creating
the carbanion to be used as a treatment for contagious and/or
infectious viruses. The mining stage is the first stage of the method
and process in the creation and usage of the carbanions. The mining
stage is the initial stage in which the process of gathering and
extracting carbon occurs. The gathering and extraction of carbon
primarily occur from different parts of corn plants and tree oils.
Some specific materials used in the process of mining are corn and
tree oils. Corn has many parts to it such as leaves, stems, grain,
roots, and cob. These different parts of corn contain many different
elemental compositions such as carbon, oxygen, hydrogen, nitrogen,
phosphorus, potassium, calcium, magnesium, sulfur, iron, silicon,
aluminum, chlorine, and manganese. In summary, carbon is obtained
through plants by the extraction of carbon dioxide. The mixture stage
is the second stage of the method and process in the creation and
usage of the carbanions. The mixture stage is the next stage after
the mining stage. In the mixture stage, the blending and mixing of
the ingredients along with the carbon from the mining stage occurs.
The said ingredients are mixed in a proprietary sequence and time to
create the solution that is ready to go under an exothermic reaction
to create the carbanion. The production stage is the third stage of
the method and process in the creation and usage of the carbanions.
The production stage is the next stage after the mixture stage. In
the production stage, an exothermic chemical reaction occurs to the
said solution from the mixture stage. The solution that is created in
the mixture stage is ready to undergo an exothermic reaction in order
to produce the carbanion within the solution. An exothermic reaction
is a chemical reaction that releases energy through light or heat, in
this case, heat is applied and used. The exothermic reaction causes
the carbon atoms within the solution to go from a neutral 6 neutrons,
6 protons, and 6 electrons configuration to a negatively charged 6
neutrons, 6 protons, and 8 electrons carbanion. The exothermic
chemical reaction that is used is a process that robs electrons from
other compounds and is given to the carbon atoms thus creating the
carbanions. A carbanion has a highly negatively charged organic
carbon, trivalent carbon atom that has eight electrons in its valence
shell. The process of adding electrons is done by using temperature
or pressure. The treatment stage is the fourth stage of the method
and process in the creation and usage of the carbanions. During the
treatment stage, the solution is ready to be used by the user with an
infectious virus. The treatment for the user requires the user to be
active with ingestion of the solution for over three days. The user
is to apply the treatment three times a day, one in the morning, one
in the afternoon, and one at night. Each treatment requires the user
to insert three droplets of the solution into a nebulizer containing
an ounce of water. The user is then to use the nebulizer to inhale
the solution that is mixed with water within the nebulizer. The
nebulizer will fog the carbanion into the lungs at 5 sextillion atoms
of carbanion per drop, these carbanion atoms are to mechanically
disassemble the vital parts of the virus as the atoms enter the
virus. The interaction between atoms and ions occurs. When the highly
charged carbanion is attached to a positive charge just like in
nature, it removes the matter at an atom level. Since the user is
applying the treatment three times per day for a duration of three
days, approximately a total of 54 sextillion carbanion atoms are used
in the process of treating the user with a virus. The carbanion binds
to the body of the virus as well as puncture the membrane and drains
vital fluids from the virus. The carbanions are made by using
physical chemistry. Physical chemistry is simply the branch of
chemistry concerned with interactions and transformation of
materials. Unlike other branches, physical chemistry deals with the
principles of physics underlying all chemical interactions, seeking
to measure, correlate, and explain the quantitative aspects of
reactions. Physical chemistry is the study of how matter behaves on a
molecular and atomic level and how chemical reactions occur. Further,
the physical chemistry involves the transformation of carbon into
carbanions with an exothermic reaction. The carbanions have been
approved by the USDA. Further, the carbanions form a product that is
made from biomass and is also biobased. The product is nearly 90%
carbon. The carbanions have been used in the treatment of multiple
viruses in the past. Some viruses in which was treated by the use of
the carbanions are arenavirus, banana mild mosaic virus, banana
virus, bean pod virus, echovirus, hantavirus, influenza virus,
morbillivirus, mosaic cucumber mosaic virus, parainfluenza virus,
paramyxovirus, parvovirus B19, poxvirus vaccinia virus, rhinovirus,
soybean mosaic virus, banana streak virus, togavirus,
varicella-zoster virus, and Yersinia pestis virus.
The
carbanions kill viruses by the elimination of strands of nucleic
acid, either DNA or RNA, and a protective protein coat (the capsid),
or a lipid envelope, surrounding the protein. The reason the
carbanions can kill the said viruses is that viruses are about 125
nanometer in size and the carbanion atoms are only about 340
picometers. But specifically, COVID-19, also known as Coronavirus, is
about 200 nanometer in size and the carbanion atoms are only about
340 picometers. The size difference is immense so that the carbanion
can penetrate and invade the interior of the virus to kill it from
the inside and attacking the vital points of a virus. The carbanion
is a carbon atom in which contains a negative charge. The valence
shell of a negatively charged carbon atom contains 8 electrons. Thus,
its octet is complete, and it contains an extra pair of electrons for
8. The negatively charged carbon is in a state of sp3 hybridization.
The hybrid orbitals are directed towards the corners of a
tetrahedron. Three of the hybrid orbitals are involved in the
formation of single covalent bonds with other atoms while the 5th
hybrid orbital contains a lone pair of electrons. Thus, it has a
pyramidal structure similar to NH3 molecule. The carbanion is a
carbon that contains eight electrons which are highly reactive
intermediate, and they are readily attacked by electrophilic
reagents. Carbanion itself is a nucleophile.
The carbanions
have had many successes throughout different viruses. The carbanions
have been used in the past on many different people on many different
viruses and have successfully treated the users.
The
treatment using the carbanions has many testimonial occurrences that
have fought off many different viruses. The occurrence is one of many
cases where the patients were to use the carbanions with a nebulizer,
three droplets a day for three days to treat COVID-19. It is also
important to note that the carbanions are able to treat many
different viruses due to similar structures since all viruses have
similar structures as the carbanions are to enter the membrane of the
virus to kill off vitals of the said virus. Some viruses in which was
treated by the use of the carbanions are arenavirus, banana mild
mosaic virus, banana virus, bean pod virus, echovirus, hantavirus,
influenza virus, morbillivirus, mosaic cucumber mosaic virus,
parainfluenza virus, paramyxovirus, parvovirus B19, poxvirus vaccinia
virus, rhinovirus, soybean mosaic virus, banana streak virus,
togavirus, varicella-zoster virus, and Yersinia pestis virus.
Further, the carbanions may be used for treating diseases associated
with different viruses.
Further, the present disclosure
describes C-therapy to facilitates treating of cancer. Unlike
traditional radiation, Carbon C- (carbanions) therapy targets cancer
with 100 sextillion C-. Since their more exact, higher, and
potentially more effective doses of radiation can be delivered,
without causing damage to surrounding healthy tissues. C-therapy
fights cancers and minimizes treatment side effects. Further
C-therapy also facilitates treating prostate cancer, head and neck
cancer, lung cancer, soft tissue cancer, pediatric cancer, breast
cancer, etc.
Further, the present disclosure describes a
compound that is used as a treatment for COVID-19 (coronavirus).
Further, the compound may be an organic compound. Further, the
compound is created by making use of the carbanion's physical
chemistry. Further, the compound may be used for treating viral
infections. Further, the compound is created by taking carbon atoms
out of a plant and using temperature to create reduction or redox to
add 2 electrons to the carbon atom generating the highly negatively
charged organic carbon atoms. Further, the highly negatively charged
organic carbon atoms puncture the membrane of the virus to release
vital fluid which causes the virus to die.
Further, the
present disclosure describes an organic compound that is used to
treat and cure lung diseases caused by viruses, bacteria, or of the
likes. Further, the present disclosure describes the use of
carbanion's physical chemistry in the creation of a compound that is
used as a lungs bacterial treatment for bacterial, fungus, virus, and
diseases related to the lungs. Further, the highly negative charged
organic carbon atoms of the organic compound puncture the membrane of
the organism such as bacteria, fungi, etc.
Further, the
present disclosure describes a compound that is used to treat and
cure skin diseases. Further, the compound may be an organic compound.
Further, the compound is created by making use of the carbanion's
physical chemistry. Further, the compound may be used as a skin
treatment/cure for skin diseases. Further, the compound is created by
taking carbon atoms out of a plant and using temperature to create
reduction or redox to add 2 electrons to the carbon atom generating
the highly negatively charged organic carbon atoms. Further, the
highly negative charged organic carbon atoms of the organic compound
puncture the membrane of the organism such as bacteria, fungi, etc.
Further, the present disclosure relates to physical
chemistry. Further, the present disclosure describes a method,
process, and usage of creating a carbanion that is used as a
treatment for contagious and/or infectious viruses.
Further,
the present disclosure describes a treatment for contagious and
infectious viruses. The present disclosure also describes a method
and process of creating a carbanion as well as the unique usage of
the carbanion as a treatment for contagious and/or infectious
viruses. Furthermore, the present disclosure describes a cheap and
cost-efficient treatment for contagious and/or infectious viruses.
The present disclosure also describes a treatment to cure multiple
known viruses and potentially undiscovered viruses.
FIG. 1 is
a table 100 listing ingredients of a medicine composition for
facilitating treating organs of a mammal, in accordance with some
embodiments. Further, the table 100 may include a column 102 and two
rows 104-106. Further, the table 100 may include two cells (column
102, row 104) and (column 102, row 106). Further, the medicine
composition may include carbanions and a diluting agent.
Further,
a cell (column 102, row 104) of the table 100 may be related to the
carbanions. Further, a carbanion of the carbanions may include a
carbon atom. Further, the carbon atom may include a formal charge of
-1.
Further, a cell (column 102, row 106) of the table 100
may be related to the diluting agent. Further, the diluting agent may
be capable of combining with the carbanions for forming at least one
appliable form of the medicine composition. Further, the diluting
agent may include at least one solvent. Further, the at least one
solvent may include water, cream, oil, etc. Further, a ratio of the
diluting agent to the carbanions by volume ranges from 512:1 to 32:1.
Further, the combining facilitates applying of the at least one
appliable form of the medicine composition to at least one organ of
the mammal. Further, the at least one organ may include lungs, skin,
etc. Further, the mammal may include a human. Further, the at least
one appliable form of the medicine composition may include a
solution, a suspension, an aerosol, an emulsion, etc.
Further,
in some embodiments, the ratio of the diluting agent to the
carbanions by the volume may be 284:1.
Further, in some
embodiments, the ratio of the diluting agent to the carbanions by the
volume may be 189:1.
Further, in some embodiments, the ratio
of the diluting agent to the carbanions by the volume may be 57:1.
In further embodiment, the medicine composition may include
an elemental composition in a ratio to the carbanions by volume.
Further, the ratio of the elemental composition to the carbanions by
the volume may be 1:9. Further, in an embodiment, the elemental
composition may include oxygen, hydrogen, nitrogen, phosphorus,
potassium, calcium, magnesium, sulfur, iron, silicon, aluminum,
chlorine, and manganese.
Further, in some embodiments, each
carbanion of the carbanions may be capable of creating an
electromechanical reaction with an organic material of at least one
organism present on the at least one organ of the mammal based on the
applying of the at least one appliable form of the medicine
composition. Further, the creating of the electromechanical reaction
disassembles the organic material of the at least one organism for
eliminating the at least one organism. Further, the eliminating of
the at least one organism facilitates the treating of the at least
one organ of the mammal. Further, the at least one organism may
include viruses, bacteria, fungi, protozoa, insects, etc. Further,
the insects may include pests, parasites, etc. Further, the organic
material of the at least one organism may include lipid, protein,
etc. Further, the at least one organism causes at least one disease
to the at least one organ. Further, the at least one disease may
include lung diseases, skin diseases, etc. Further, the lung diseases
may include COVID-19. Further, the skin disease may include gangrene.
Further, in some embodiments, the carbanions may be derived
from at least one organic material. Further, the at least one organic
material may be associated with at least one part of at least one
plant. Further, the at least one plant may include a corn plant.
Further, the at least one part of the corn plant may include a leaf,
a stem, a grain, a root, and a cob.
Further, in some
embodiments, the diluting agent may include at least one cream.
Further, the at least one cream may include a shea butter.
Further,
in some embodiments, the diluting agent may include at least one
moisturizing element.
FIG. 2 is a flowchart of a method 200
for facilitating treating organs of a mammal using a medicine
composition, in accordance with some embodiments. Further, at 202 the
method 200 may include a step of transforming, using at least one
application device, the medicine composition into at least one
appliable form. Further, the medicine composition may include
carbanions and a diluting agent. Further, a carbanion of the
carbanions may include a carbon atom. Further, the carbon atom may
include a formal charge of -1. Further, the diluting agent may be
capable of combining with the carbanions for forming the at least one
appliable form of the medicine composition. Further, the at least one
appliable form of the medicine composition may include a solution, a
suspension, an aerosol, an emulsion, etc. Further, a ratio of the
diluting agent to the carbanions by volume ranges from 512:1 to 32:1.
Further, at 204, the method 200 may include a step of
applying, using the at least one application device, at least one
dosage of the at least one appliable form of the medicine composition
on at least one organ of the mammal based on the transforming.
Further, the applying of the at least one dosage of the at least one
appliable form of the medicine composition facilitates the treating
of the at least one organ of the mammal. Further, the at least one
organ may include lungs, skin, etc. Further, the mammal may include a
human.
Further, in some embodiments, the at least one
application device may include a nebulizer. Further, the at least one
organ may include at least one lung. Further, the at least one
appliable form of the medicine composition may include an aerosol.
Further, the transforming may include aerosolizing the medicine
composition into the aerosol. Further, the applying may include
delivering the aerosol to the at least one lung of the mammal.
Further, in some embodiments, the at least one application
device may include an emulsifier. Further, the at least one organ may
include skin. Further, the at least one appliable form of the
medicine composition may include an emulsion. Further, the
transforming may include emulsifying the medicine composition into
the emulsion. Further, the applying may include covering the skin of
the mammal with the emulsion.
In further embodiments, the
method 200 may include a step of generating, using the at least one
application device, the at least one dosage of the at least one
appliable form of the medicine composition. Further, the applying of
the at least one dosage of the at least one appliable form of the
medicine composition may be based on the generating of the at least
one dosage.
Further, in some embodiments, the at least one
dosage of the at least one appliable form of the medicine composition
may include one ounce of water and at least three drops of the
carbanions. Further, the diluting agent may include the water.
Further, one drop of the carbanions may include 5 sextillion carbon
atoms. Further, one ounce may include 353 drops.
Further, in
some embodiments, the treating of the at least one organ may include
eliminating at least one organism from the at least one organ causing
at least one disease in the at least one organ of the mammal based on
the applying. Further, the eliminating may include disassembling an
organic material of the at least one organism based on an interaction
of the carbanions with the organic material based on the applying.
Further, the at least one organism may include viruses, bacteria,
fungi, protozoa, insects, etc. Further, the insects may include
pests, parasites, etc. Further, the organic material of the at least
one organism may include lipid, protein, etc. Further, the at least
one organism causes at least one disease to the at least one organ.
Further, the at least one disease may include lung diseases, skin
diseases, etc. Further, the lung diseases may include COVID-19.
Further, the skin disease may include gangrene.
Further, in
some embodiments, the treating of the at least one organ may include
regenerating at least one tissue of the at least one organ of the
mammal based on the applying. Further, the at least one disease
causes degeneration of the at least one tissue of the at least one
organ.
Further, in some embodiments, the at least one dosage
of the at least one appliable form of the medicine composition may be
associated with a dosing frequency. Further, the dosing frequency may
include three times a day for at least one three days. Further, the
applying of the at least one dosage of the at least one appliable
form of the medicine composition with the dosing frequency
facilitates the treating of the at least one organ.
Further,
in some embodiments, the applying of the at least one appliable form
of the medicine composition may be associated with an applying
duration. Further, the at least one applying duration may include at
least one minute, at least one hour, etc. Further, the treating of
the at least one organ may be based on the applying of the at least
one appliable form of the medicine composition for the applying
duration.
Further, in some embodiments, the at least one
appliable form of the medicine composition may include a solution.
Further, the solution may be appliable to the at least one organ
using at least one application method. Further, the at least one
application method may include soaking, washing, inhaling, gargling,
rinsing, etc. Further, the applying of the solution of the medicine
composition to the at least one organ facilitates the treating of the
at least one organ.
FIG. 3 is an illustration of carbanions
300 of the medicine composition, in accordance with some embodiments.
Further, the carbanions 300 may be derived from at least one organic
material source. Further, the at least one organic material source
may include at least one plant. Further, the carbanions 300 may
include carbon atoms extracted from the at least one plant. Further,
the carbanions 300 may include a 100% organic matter. Further, the
organic matter may be organic carbon atoms. Further, at least one of
a specific temperature and a specific pressure may be applied to the
carbon atoms for initiating at least one of a reduction reaction and
a redox reaction. Further, the at least one of the reduction reaction
and the redox reaction adds 2 electrons to the carbon atoms for
creating negatively charged carbon atoms. Further, each negatively
charged carbon atom of the negatively charged carbon atoms may
include 8 electrons and 6 protons, and 6 neutrons. Further, the
negatively charged carbon atoms may be highly negatively charged.
Further, the negatively charged carbon atoms may be the carbanions
300. Further, the carbanions 300 may include a trivalent carbon atom
comprising eight (8) electrons in the valence shell of the trivalent
carbon atom. Further, the carbanions 300 may be created using
physical chemistry of the carbanions 300. Further, the carbanions 300
may include micelles structures. Further, the micelles structure may
include a spherical shape.
FIG. 4 is a front view of a container
400 containing the medicine composition, in accordance with some
embodiments. Further, the medicine composition may include the
carbanions and the diluting agent. Further, the medicine composition
may be configured for treating the organs of the mammal. Further, the
organs may have at least one disease. Further, the treating may
include curing the at least one disease associated with the organs.
Further, the organs may include lungs, skin, etc. of the mammal.
Further, the mammal may include a human and an animal. Further, the
at least one disease may include lung diseases, skin diseases, etc.
Further, the lung diseases may include COVID-19. Further, the skin
diseases may include gangrene. Further, at least one of fungi,
bacteria, viruses, and insects may cause the at least one disease.
Further, the insects may include pests, parasites, etc. Further, the
carbanions may be derived from at least one organic source. Further,
the at least one organic source may include at least one plant.
Further, the carbanions may include 100% organic matter. Further, the
organic matter may include organic carbon atoms. Further, the
carbanions may include carbon atoms. Further, the carbon atoms may be
extracted from the at least one plant. Further, at least one of a
specific temperature and a specific pressure may be applied to the
carbon atoms for initiating at least one of a reduction reaction and
a redox reaction. Further, the initiating of the at least one of the
reduction reaction and the redox reaction may add 2 electrons to the
carbon atoms creating negatively charged carbon atoms. Further, each
negatively charged carbon atom of the negatively charged carbon atoms
may include 8 electrons and 6 protons, and 6 neutrons. Further, the
negatively charged carbon atoms may be highly negatively charged.
Further, the negatively charged carbon atoms may be the carbanions.
Further, the carbanions may include a trivalent carbon atom
comprising eight (8) electrons in the valence shell of the trivalent
carbon atom. Further, the negatively charged carbon atoms may be
created using the physical chemistry of the carbanions. Further, the
negatively charged carbon atoms may be configured for puncturing the
membrane of the at least one of the fungi, the bacteria, the viruses,
and the insects. Further, the puncturing of the membrane makes the at
least one of the fungi, the bacteria, the viruses, and the insects
may eliminate the at least one of the fungi, the bacteria, the
viruses, and the insects. Further, the puncturing of the membrane
makes the at least one of the fungi, the bacteria, the viruses, and
the insects inactive and facilitates treating the organs.
Further,
in some embodiments, the puncturing of the membrane of the at least
one of the fungi, the bacteria, the viruses, and the insects may
release vital fluids of the at least one of the fungi, the bacteria,
the viruses, and the insects. Further, the release of the vital
fluids may cause the death of the at least one of the fungi, the
bacteria, the viruses, and the insects making the at least one of the
fungi, the bacteria, the viruses, and the insects inactive. Further,
the death of the at least one of the fungi, the bacteria, the
viruses, and the insects may facilitate the treating of the organs.
Further, in some embodiments, the at least one disease may
include bacterial diseases associated with the bacteria. Further, the
organs may have the bacterial diseases Further, the bacterial
diseases may include Bronchitis, Chronic Cough, Common Cold,
Influenza, Pertussis, Pleurisy, Pneumonia, Sarcoidosis, Spirometry,
Sudden Infant Death Syndrome (SIDS), Tuberculosis, actinomycosis,
Anthrax, boutonneuse fever, brucellosis, brucellosis spondylitis,
campylobacteriosis, Carrion disease, cat scratch disease, cervicitis,
chancroid, chlamydia, lymphogranuloma venereum, cholera, clostridial
infection, dysentery, shigellosis, epididymitis, erysipelothrix
infection, glanders, gonorrhea, granuloma inguinale, Legionnaire
disease, Leprosy, leptospirosis, listeriosis, Lyme disease,
Melioidosis, nocardiosis, paratyphoid fever, pharyngitis, plague,
bubonic plague, pneumonia, proctitis, pseudotuberculosis,
psittacosis, Q fever, rat-bite fever, Reiter syndrome, relapsing
fever, rheumatic fever, Rocky Mountain spotted fever, Salmonellosis,
scarlet fever, septicemia, Waterhouse-Friderichsen syndrome,
Shigellosis, streptobacillary fever, syphilis, bejel, gumma, yaws,
tetanus, tonsillitis, toxic shock syndrome, trench fever,
tuberculosis, scrofula, tularemia, typhoid fever, typhus, scrub
typhus, urethritis, vaginitis, vesiculitis, vulvitis, whooping cough,
yersiniosis, etc.
Further, in some embodiments, the at least
one disease may include fungal diseases associated with the fungi.
Further, the organs may have the fungal diseases. Further, the fungal
diseases may include Aspergillosis, Cryptococcosis, Candidiasis,
Mucormycosis, Pneumocystis jirovecii Pneumonia, aspergillosis,
Blastomycosis, candidiasis, thrush, chromoblastomycosis,
coccidioidomycosis, cryptococcosis, histoplasmosis, pharyngitis,
pneumonia, sporotrichosis, urethritis, vaginitis, vulvitis, etc.
Further, in some embodiments, the at least one disease may
include protozoa diseases associated with protozoa. Further, the
organs may have the protozoa diseases. Further, the protozoa diseases
may include avian malaria, Chagas disease, Coccidiosis,
leishmaniasis, Oriental sore, Malaria, blackwater fever, sleeping
sickness, toxoplasmosis, trichomoniasis, trypanosomiasis, etc
Further, in some embodiments, the treating of the lungs and
the curing of the lung diseases may include an application of the
medicine composition to the lungs. Further, the application may
include at least one of inhaling, gargling, drinking, etc. Further,
the application may be associated with at least one duration.
Further, the at least one duration may include at least one second,
at least one minute, at least one hour, etc. Further, the application
may be repeated after at least one second duration of at least one
first duration. Further, the at least one first duration may include
at least one first minute, at least one first hour, at least one
first day. Further, the at least one second duration may include at
least one second minute, at least one second hour, at least one
second day. Further, in an embodiment, the application may include at
least three applications in a day for three days. Further, each
application of the at least three applications may include a dosage
of the carbanions. Further, the dosage may include 2 to 10 drops.
Further, 1 drop may include 5 sextillion carbanions. Further, the
2-10 drops may include 10 to 50 sextillion carbanions.
Further,
in some embodiments, the medicine composition may be administered
using a nebulizer. Further, the nebulizer may use a solution of the
medicine composition. Further, the solution may include at least
three drops of the carbanions mixed with an ounce of the water.
Further, the nebulizer may turn the solution into a mist for inhaling
the solution. Further, the at least one of the humans and the animals
may inhale the mist. Further, the inhaling of the mist may facilitate
the treating of the organs and the curing of the diseases. Further,
the inhaling of the solution three times a day for at least three
days facilitate the treating and the curing. Further, one drop of the
carbanions may include 5 sextillion carbon atoms. Further, one ounce
may include 353 drops.
Further, in some embodiments, the
treating of the skin and the curing of the skin diseases may include
an application of the medicine composition on the skin. Further, the
application may include at least one of rubbing, massaging, coating,
soaking, washing, spraying, etc. Further, the application may be
associated with at least one duration. Further, the at least one
duration may include at least one second, at least one minute, at
least one hour, etc. Further, the application may be repeated after
at least one second duration of at least one first duration. Further,
the at least one first duration may include at least one first
minute, at least one first hour, at least one first day. Further, the
at least one second duration may include at least one second minute,
at least one second hour, at least one second day.
Further,
in some embodiments, the treating of the skin and the curing of the
skin diseases may include regenerating the skin of at least one body
part of the human. Further, the at least one of the treating and the
curing may include growing of the skin on the at least one body part.
Further, in some embodiments, the skin diseases may be
associated with skin conditions of the skin. Further, the skin
conditions may include burns, acne, infections of the skin. Further,
a PicoSkin comprising the medicine composition may be used to prevent
infection in second and third-degree burns. Further, PicoSkin may be
sprayed on the burns affected areas of the skin multiple times per
day. Further, the PicoSkin may be applied on the acne-affected areas
of the skin. Further, the PicoSkin may reduce skin oil and kill
infections. Further, the infection on the skin may include bacterial
infections, fungal infections, yeast, viral, Ricketsial, and chemical
burns. Further, the PicoSkin may cure the infection on the skin.
Further, in some embodiments, the medicine composition may be
used in a cream. Further, the cream may be applied twice a day for
two days. Further, the cream may include Shea butter. Further, twice
the day may include a morning time and a bed time. Further, each of
the morning time and the bed time may be associated with a dosage of
the carbanions. Further, the dosage may include 1/3 oz. Further, 1 oz
may include 353 drops. Further, the 1/3 oz may be 118 drops. Further,
1 drop may include 5 sextillion carbanions. Further, the 118 drops
may include 590 sextillion carbanions.
Further, in some
embodiments, a "Pico Skin Relief" comprising the medicine
composition. Further, the "Pico Skin Relief" may be a 100%
concentrate in liquid or cream. Further, the "Pico Skin Relief"
may be a 100% concentrate made of US Government FDA EAFUS food
additives. Further, the "Pico Skin Relief" may be like a
single element, not a chemical compound. Further, the "Pico Skin
Relief" may be safe for ingestion and inhalation. Further, the
"Pico Skin Relief" may be applied to the internal and
external skin of the at least one body part. Further, the "Pico
Skin Relief" may be cosmetic moisturizer for skin issues of
debriding, cleansing wash, to promote healing and or pain relief.
Further, the "Pico Skin Relief" may be used for skin issues
of skin softening, bio-films, crust, scab, divots, fungal, molds,
sun-spots, granules, inflammation, lesions, ulcers, itchy, skin loss,
oozing, sores, wounds, pigment changes, pimples, rashes, scabbing,
shards, leathery skin, callus, and dry skin. Also, it helps with skin
sensations of biting, burning, crawling, creeping, itching, pricking,
pinching, and stinging. Further, the "Pico Skin Relief" may
be available as a liquid or cream product.
Further, in an
embodiment, the skin diseases may include Genetic Blistering, Dog Ear
Infection, Lamb Gangrene Infection, MRSA, Psoriasis, Squamous Cancer,
Arm Dandruff, Ringworms, Whooping Cough Pneumonia, Parasite Scabies,
Basal Cell Cyst, Cellulitis, Head Lice, Lupus, etc. Further, the
"Pico Skin Relief" may facilitate the treating of the skin
and the curing of the skin diseases.
Further, in an
embodiment, the skin diseases may include gangrene. Further, the
gangrene may be associated with the at least one body part. Further,
the gangrene may be a potentially life-threatening condition that
arises when a considerable mass of body tissue dies (necrosis).
Further, the gangrene may occur after an injury or infection, or in
people suffering from any chronic health problem affecting blood
circulation. Further, the primary cause of gangrene may be reduced
blood supply to the affected tissues, which results in cell death.
Further, the gangrene may be caused by ischemia or infection, such as
by the bacteria Clostridium perfringens or by thrombosis (a blood
vessel blocked by a blood clot). Further, the gangrene may be usually
the result of critically insufficient blood supply (e.g., peripheral
vascular disease) and may be often associated with diabetes and
long-term tobacco smoking. Further, the gangrene may be most common
in the lower extremities (such as the leg). The best medical
treatment today for the gangrene may be revascularization (i.e.,
restoration of blood flow) of the afflicted organ, which can reverse
some of the effects of necrosis and allow healing. Further, the other
treatment of the gangrene may include debridement and surgical
amputation. Further, the method of treatment may be generally
determined by the location of affected tissue and the extent of
tissue loss.
Further, the treatment of the gangrene may
include applying a moisturizer. Further, the moisturizer may be made
up of 90% of 600 (Pico meter) carbon particles. Further, the
treatment may eliminate the gangrene. Further, the treatment may
eliminate the wound of the gangrene. Further, the treatment may make
the skin grow from the edges to the center of the gangrene wound.
Further, the treatment may cure the gangrene without the reduction of
body parts affected by the gangrene. Further, the gangrene may cause
the Gangrene Black on the body parts. Further, the application of
"Pico Skin Relief" may remove the Gangrene Black. Further,
the "Pico Skin Relief" may include the carbanions. Further,
the application of the "Pico Skin Relief" starts the
process of skin growth on the body parts. Further, the application of
the "Pico Skin Relief" for at least three days may cause a
100% reduction in the black Gangrene part on foot. Further, the
application of the "Pico Skin Relief" may cause growth in
the tissue on an upper part of the foot. Further, the application of
the "Pico Skin Relief" may cause the skin to grow and
reverse the damage caused by the gangrene on the foot. Further, the
application of the "Pico Skin Relief" may include 4 oz per
gallon dilution. Further, the application may include three
foot-baths daily for 30 min. Further, the application may cause the
forming of tan-colored covering. Further, the tan-colored forming may
be mucoid exudate that forms on the healing of a full thickness wound
of the gangrene. Further, skin form over an entire surface at one
time other than skin cells being sprayed onto a matrix placed on a
skinless wound. Further, the "Pico Skin Relief" may replace
the traditional treatment of the gangrene. Further, the traditional
treatment may include surgical debridement, wound care, and
antibiotic therapy, and amputation is necessary in many cases.
Further, the amputation may be performed for an ischemic disease of
the lower extremity. Of dysvascular amputations, 15-28% of patients
undergo contralateral limb amputations within 3 years. Of elderly
persons who undergo amputations, 50% survive the first 3 years.
Further, the treatment using the "Pico Skin Relief" may
cure the gangrene without performing the amputation.
Further,
the "Pico Skin Relief" may be used for treating the
gangrene. Further, the treating may eliminate the gangrene without
the amputation of the affected body part (such as legs). Further, the
"Pico Skin Relief" may be used in 4 oz per gallon dilution.
Further, the treating of the gangrene may include at least three
applications of the "Pico Skin Relief" to the leg for at
least thirty minutes. Further, the treating of the gangrene may
include removal of gangrene black of the leg, growth in the skin of
the leg, and formation of tissue on the leg.
Further, in some
embodiments, the carbanions may control gram-positive bacteria at
16,000 of the water to 1. Further, the carbanions may control the
gram-positive bacteria at 1 ml to 16 liters of water.
Further,
in some embodiments, a carbanion of the carbanions may be an anion in
which carbon bears a formal negative charge. Further, the carbanion
may include eight electrons in the valence shell of the carbon.
Further, a carbon-atom of the carbanion may include a negative
charge. Further, the valence shell of a negatively charged carbon
atom may include 8-electrons. Further, the octet of the negatively
charged carbon atom may be complete. Further, the negatively charged
carbon atom may include an extra pair of electrons. Further, the
negatively charged carbon atom may be in a state of sp3
hybridization. Further, the hybrid orbitals may be directed towards
the corners of a tetrahedron. Further, three hybrid orbitals may be
involved in the formation of single covalent bonds with other atoms
while the fourth hybrid orbital may include a lone pair of electrons.
Further, the carbanion may include a pyramidal structure similar to
NH3 (Ammonia) molecule. Further, the carbon-atom may include eight
electrons. Further, the carbon-atom may be a highly reactive
intermediate. Further, the carbon-atom may be readily attacked by
electrophilic reagents. Further, the carbanion may be a nucleophile.
Further, the carbanion may include "Negative Octet
Energy". Further, the carbanion may be an anion in which the
carbon-atom bears a formal negative charge. Further, in an
embodiment, the carbanion may include a single negatively charged
carbon atom. Further, the single negatively charged carbon atom bonds
to no other atoms except for another single negatively charged carbon
atom.
FIG. 5 is a plot of light scattering by the carbanions
through a dynamic light scattering, in accordance with some
embodiments. Further, the dynamic light scattering may be a technique
for measuring a particle size. Further, the particle size range from
a few nanometers (nm) to a few microns. Further, the light intensity
may be proportional to the size of "aggregates". Further,
the dynamic light scattering may be an excellent tool for
translocation. Further, 0.6 nm peaks may show greater
intensity-weight distribution. Further, large aggregates scatter the
storing light for 0.6 nm peak. Further, most micelles may be 0.6 nm
in particle size hydrodynamic radius.
FIG. 6 is a magnified
view of a sample of a solution of the medicine composition, in
accordance with some embodiments. Further, the solution may include a
1:1 dilution. Further, the sample of the solution may be magnified up
to 100,000.times.. Further, the sample of the solution may include
droplets with small grains. Further, the droplets may include the
carbanions.
FIG. 7 is a magnified view of a sample of the
solution, in accordance with some embodiments. Further, the solution
may include a 1:1 dilution. Further, the sample of the solution may
be magnified up to 100,000.times.. Further, the sample of the
solution may include droplets with small grains. Further, the
droplets may include the carbanions.
FIG. 8 is a magnified
view of a sample of a solution of the medicine composition, in
accordance with some embodiments. Further, the solution may include a
1:100 dilution. Further, the sample of the solution may be magnified
up to 100,000.times.. Further, the sample of the solution may include
droplets with small grains. Further, the droplets may include the
carbanions.
FIG. 9 is a magnified view of a sample of the
solution, in accordance with some embodiments. Further, the solution
may include a 1:100 dilution. Further, the sample of the solution may
be magnified up to 100,000.times.. Further, the sample of the
solution may include droplets with small grains. Further, the
droplets may include the carbanions.
FIG. 10 is a magnified
view of a sample of a solution of the medicine composition, in
accordance with some embodiments. Further, the solution may include a
straight solution. Further, the solution may be magnified up to
100,000.times.. Further, the sample of the solution may include
droplets. Further, the droplets may include similar size particles
around the edges, but inside, the grain is less than 1 nm
(nanometer). Further, the droplets may include the carbanions.
FIG.
11 is a schematic of a carbanion 1100 of the carbanions, in
accordance with some embodiments. Further, the carbanion 1100 is an
anion in which carbon bears a formal negative charge. Further, the
carbanion 1100 may include eight electrons in the valence shell of
the carbon. Further, a carbon-atom of the carbanion 1100 may include
a negative charge. Further, the valence shell of a negatively charged
carbon-atom may include 8-electrons. Further, the octet of the
negatively charged carbon atom may be complete. Further, the
negatively charged carbon atom may include an extra pair of
electrons. Further, the negatively charged carbon may be in a state
of sp3 hybridization. Further, the hybrid orbitals may be directed
towards the corners of a tetrahedron. Further, three of the hybrid
orbitals may be involved in the formation of single covalent bonds
with other atoms while the fourth hybrid orbital may include a lone
pair of electrons. Further, the carbanion 1100 may include a
pyramidal structure similar to NH3 molecule. Further, the carbon-atom
may include eight electrons even the carbon-atom may be a highly
reactive intermediate. Further, the carbon-atom may be readily
attacked by electrophilic reagents. Further, the carbanion 1100 may
be a nucleophile.
FIG. 12 is an illustration of gram-positive
bacteria. Further, the gram-positive bacteria retain crystal violet
dye and stain dark violet or purple. Further, the gram-positive
bacteria remain blue or purple colored with gram stain when washed
with absolute alcohol and water. Further, the gram-positive bacteria
may include a thick (multilayered) Peptidoglycan layer. Further,
Teichoic acids may be present in most of the gram-positive bacteria.
Further, Periplasmic space is absent in the gram-positive bacteria.
Further, an outer membrane is absent in the gram-positive bacteria.
Further, Lipopolysaccharide (LPS) content is virtually absent in the
gram-positive bacteria. Further, the gram-positive bacteria may
include low Lipid and lipoprotein content. Further, acid-fast
bacteria may have lipids linked to peptidoglycan. Further, the
gram-positive bacteria may primarily produce Exotoxins. Further, a
flagellar structure of the gram-positive bacteria may include 2 rings
in the basal body. Further, the gram-positive bacteria may have high
resistance to physical disruption. Further, the gram-positive
bacteria may have high inhibition by basic dyes. Further, the
gram-positive bacteria may have a high susceptibility to anionic
detergents. Further, the gram-positive bacteria may have high
resistance to sodium azide. Further, the gram-positive bacteria may
have high resistance to drying. Further, the cell wall of the
gram-positive bacteria is 100-120 .ANG. thick and single-layered. The
lipid content of the cell wall is low, whereas Murein content is
70-80% (higher). Further, Mesosome is more prominent in the
gram-positive bacteria. Further, the gram-positive bacteria are more
susceptible to antibiotics.
FIG. 13 is an illustration of
gram-negative bacteria. Further, the gram-negative bacteria may be
decolorized to accept counterstain (Safranin or Fuchsine) to stain
red or pink. Further, the gram-negative bacteria do not retain the
Gram stain when washed with absolute alcohol and acetone. Further,
the gram-negative bacteria may include a thin (single-layered)
Peptidoglycan layer. Further, Teichoic acids are absent in most of
the gram-negative bacteria. Further, Periplasmic space is present in
gram-negative bacteria. Further, an outer membrane is present in the
gram-negative bacteria. Further, Lipopolysaccharide (LPS) content is
high in the gram-negative bacteria. Further, the gram-negative
bacteria may include a high lipid and lipoprotein content due to the
presence of the outer membrane. Further, the gram-negative bacteria
may primarily produce Endotoxins. Further, a flagellar structure of
the gram-negative bacteria may include 4 rings in the basal body.
Further, the gram-negative bacteria may have a low resistance to
physical disruption. Further, the gram-negative bacteria may have low
inhibition by basic dyes. Further, the gram-negative bacteria may
have low susceptibility to anionic detergents. Further, the
gram-negative bacteria may have a low resistance to sodium azide.
Further, the gram-negative bacteria may have a low resistance to
drying. Further, the cell wall of the gram-negative bacteria is
70-120 .ANG. (angstrom) thick and two-layered. Further, Lipid content
is 20-30% (high) and Murein content is 10-20% (low). Further,
Mesosome is less prominent in the gram-negative bacteria. Further,
the gram-negative bacteria are more resistant to antibiotics.
Further, the gram-positive bacteria and the gram-negative
bacteria are differentiated based on the structural differences in
cell walls of the gram-positive bacteria and the gram-negative
bacteria. Gram-positive bacteria retain the crystal violet dye do so
because of a thick layer of peptidoglycan. In contrast, Gram-negative
bacteria do not retain the violet dye and are colored red or pink.
Compared with Gram-positive bacteria, Gram-negative bacteria are more
resistant against antibodies because of the impenetrable cell wall.
Further, the gram-positive bacteria and the gram-negative bacteria
have a wide variety of applications ranging from medical treatment to
industrial use and Swiss cheese production.
Further, the
microscopic view of dental plaque shows Gram-positive bacteria
(purple) and gram-negative bacteria (red). Further, in a Gram stain
test, the gram-positive bacteria and the gram-negative bacteria are
washed with a decolorizing solution after being dyed with crystal
violet. On adding a counterstain such as safranin or fuchsine after
washing, Gram-negative bacteria are stained red or pink while
Gram-positive bacteria retain crystal violet dye. This is due to the
difference in the structure of the bacterial cell wall of the
gram-positive bacteria and the gram-negative bacteria. Gram-positive
bacteria do not have an outer cell membrane found in Gram-negative
bacteria. The cell wall of Gram-positive bacteria is high in
peptidoglycan which is responsible for retaining the crystal violet
dye.
Further, both gram-positive bacteria and gram-negative
bacteria may be pathogenic. Further, six gram-positive genera of
bacteria are known to cause disease in humans: Streptococcus,
Staphylococcus, Corynebacterium, Listeria, Bacillus, and Clostridium.
Another three cause diseases in plants: Rathybacter, Leifsonia, and
Clavibacter. Many gram-negative bacteria are also pathogenic e.g.,
Pseudomonas aeruginosa, Neisseria gonorrhoeae, Chlamydia trachomatis,
and Yersinia pestis. Gram-negative bacteria are also more resistant
to antibiotics because the outer membrane may include a complex
lipopolysaccharide (LPS) whose lipid portion acts as an endotoxin.
Further, a lot of Gram-negative bacteria are resistant to a
number of important antibiotics that are used to treat the
gram-negative bacteria. Further, agents like Acinetobacter,
Pseudomonas, E. coli. Further, the gram-negative bacteria have very
quickly developed resistance to antibiotics. Gram-negative agents
becoming very rapidly more and more resistant to all of the agents.
Greater resistance of gram-negative bacteria also applies to a newly
discovered class of antibiotics. Further, the drugs are not likely to
work on gram-negative bacteria. Further, bacteria are classified
based on the cell shape into bacilli (rod-shaped) and cocci
(sphere-shaped). Typical Gram-positive cocci stains include Clusters:
usually characteristic of Staphylococcus, such as S. aureus, Chain:
usually characteristic of Streptococcus, such as S. pneumoniae, B
group streptococci, Tetrad: usually characteristic of Micrococcus.
Further, gram-positive bacilli tend to be thick, thin, or
branching.
Further, many streptococcal species are
nonpathogenic and form part of the commensal human microbiome of the
mouth, skin, intestine, and upper respiratory tract. Further, the
streptococcal species is also a necessary ingredient in producing
Emmentaler (Swiss) cheese. Non-pathogenic species of corynebacterium
are used in the industrial production of amino acids, nucleotides,
bioconversion of steroids, degradation of hydrocarbons, cheese aging,
production of enzymes, etc. Many Bacillus species are able to secrete
large quantities of enzymes. Bacillus amyloliquefaciens is the source
of a natural antibiotic protein barnase (a ribonuclease), alpha
amylase used in starch hydrolysis, the protease subtilisin used with
detergents, and the BamH1 restriction enzyme used in DNA research. C.
thermocellum may utilize lignocellulose waste and generate ethanol,
thus making it a possible candidate for use in the production of
ethanol fuel. It is anaerobic and is thermophilic, which reduces
cooling costs. C. acetobutylicum, also known as the Weizmann
organism, was first used by Chaim Weizmann to produce acetone and
biobutanol from starch in 1916 for the production of gunpowder and
TNT. C. botulinum produces a potentially lethal neurotoxin that is
used in a diluted form in the drug Botox. It is also used to treat
spasmodic torticollis and provides relief for approximately 12 to 16
weeks. The anaerobic bacterium C. ljungdahlii may produce ethanol
from single-carbon sources including synthesis gas, a mixture of
carbon monoxide, and hydrogen that may be generated from the partial
combustion of either fossil fuels or biomass. Gram-indeterminate and
Gram-variable Bacteria
Not all bacteria may be reliably
classified through Gram staining. For example, acid-fast bacteria or
Gram-variable do not respond to Gram staining.
FIG. 14 is an
illustration of an effect of NG 1 on Alternaria alternata, in
accordance with some embodiments.
FIG. 15 is an illustration
of an effect of NG 2 on Sclerotium rolfsii, in accordance with some
embodiments.
FIG. 16 is an illustration of an effect of NG 1
on Macrophomina phaseolina, in accordance with some embodiments.
FIG. 17 is a table 1700 of an initial screen of pathogens vs.
dilution of Formula S-101, in accordance with some embodiments.
Further, the initial screen may include results at 96 hours after
treatment for 22 hours. Further, the Formula S-101 may include the
carbanions. Further, the initial screen may be associated with an
evaluation of Formula S-101 and S-102 for activity against
gram-positive plant pathogenic bacteria using pico-technology 340
pm/600 pm.
Further, Pico-technology 340 pm/600 pm Evaluation
of Formula S-100 was effective in vitro at multiple concentrations in
killing multiple isolates of agriculturally important Gram-positive
plant pathogens. The bacteria tested in these assays were Clavibacter
michiganensis subsp. nebraskensis (causal agent of Goss's wilt and
blight of maize), CI. mich. subsp. michiganensis (causal agent of
bacterial canker of tomato), CI. mich. subsp. insidiosus (causal
agent of bacterial wilt of alfalfa), and Curtobacterium
flaccumfaciens pv. flaccumfaciens (causal agent of bacterial wilt of
dry bean). The three subspecies of Clavibacter michiganensis tested
had indistinguishable sensitivities to Formula S-100 after 22 hours
treatment (2.sup.-14= 1/16384, or 61 ppm), while Curtobacterium
flaccumfaciens pv. flaccumfaciens was much less sensitive (2.sup.-8=
1/256, or 3.9 ppt). One replicate of a subset of strains was tested
after 2 hours of treatment; this shorter exposure time was nearly as
effective as 22 hours. Further, Formula S-100 was tested in vitro at
multiple concentrations to assess its potential efficacy as a
protection agent against important Gram-positive plant pathogenic
bacteria in a greenhouse and field-grown crops. Further, materials
and methods associated with the evaluation may include test
organisms. Further, the test organisms may include Clavibacter
michiganensis subsp. nebraskensis (Cmn) Disease: Goss' wilt and
blight of maize. Further, the test organisms may include Clavibacter
michiganensis subsp. michiganensis (Cmm) Disease: bacterial canker of
tomato. Further, the test organisms may include Clavibacter
michiganensis subsp. insidiosus (Cmi) Disease: bacterial wilt of
alfalfa. Further, the test organisms may include Curtobacterium
flaccumfaciens pv. flaccumfaciens (Cff) Disease: bacterial wilt of
dry bean.
Further, Bacterial cultures had been maintained as
lyophilized cultures or in Microbank vials (PRO-LAB Diagnostics,
Canada) at -70.degree. C. Culture suspensions, made from colonies
grown on Tryptic Soy Agar, were grown for two to three hours in 10 ml
Tryptic Soy Broth (Difco, Sparks, MD) at 27.degree. C., sessile. The
optical density of each culture was determined spectrophotometrically
at 640.
Further, tested in this assay was the Formula S-100
non-toxic surfactant an amber and a viscous solution. Further, a
modified Minimal Inhibitory Concentration (MIC) microbiological assay
was used to determine levels of resistance of plant pathogens to this
agent. Briefly, this method involves serial dilutions (1:2) of the
test agent in TSB, a liquid growth medium. After the dilutions were
made, an aliquot of bacterial suspensions was added to each tube,
except for an uninoculated control. The tubes were incubated for 22
hours, shaking, at 27.degree. C. Three 10 .mu.L aliquots from each
dilution were placed on the surface of a TSA plate, and the plates
were incubated at 27.degree. C. for 96 hours.
For the first
assay, as shown in FIG. 17, the test agent was diluted in ten
replicates: One milliliter of Formula S-100 concentrate was added to
1 ml of the first tube of the series and mixed; 1 ml of this tube was
transferred to the second tube of 1 ml and mixed. The dilution
process was repeated in subsequent tubes resulting in a final series
which included the undiluted agent, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64,
1:128, 1:256, 1:512, and 1:1024 dilutions.
For the second
assay, as shown in FIG. 18, FIG. 19, and FIG. 20, the test agent was
serially diluted as a single replicate, but in sufficient volume to
dispense one-milliliter aliquots for each of the two replicates of
each strain tested. This dilution series extended from the undiluted
agent out to 1:131,072, in two-fold dilutions.
For each of
the assays, control tubes were included: broth only and
bacteria+broth (no agent). Additional control was included for the
second assay: the dilution series with no bacteria added was checked
for the absence of contaminating bacteria. Each bacterial isolate was
tested in two replicate dilutions of the treatment.
The
Minimum Inhibitory Concentration of an agent is the highest dilution
or lowest concentration which prevents the growth of a bacterial
culture. In a standard MIC assay, bacterial growth is assessed after
incubation by comparing each tube of the dilution series visually or
turbidimetrically against the control tube which contains the
bacterial suspension with no test agent. We modified the MIC protocol
by plating triplicate 10 f.iL aliquots of each test dilution and
controls on TSA II.TM. Trypticase Soy Agar (BBL, Cockeysville, Md.)
medium to validate and quantitate bacterial survival. The assay
plates were incubated at 27.degree. C., examined every 24 hours, and
bacterial growth was recorded for controls and each dilution 96 hours
after inoculation. The assay plates were kept for an additional 10-12
days at 27.degree. C. to determine whether there were any "escapes"
or additional surviving cells.
Further, the results of
independent assays are presented in table format and attached. The
growth of bacteria was recorded as positive (+) or negative (-) based
on visible growth in the areas of inoculum (triplicate spots) on the
agar plates. The minimum inhibitory concentration of agents is
indicated on the tables by a yellow shading of cells; growth of
bacteria by green shading.
The three subspecies of
Clavibacter michiganensis tested had indistinguishable sensitivities
to Formula S-100, not surprising given the extensively confirmed
relatedness. Curtobacterium flaccumfaciens pv. flaccumfaciens was
much less sensitive, a surprising result because this pathogen is
closely related to the other three.
There are limited
bacterial control agents currently registered for crop protection.
Screening for cost-effective bactericides including bio-based,
synthetic, and inorganic compounds frequently begins in the
laboratory within vitro assays to evaluate the activity of the agent
against target organisms in a non-plant system under standardized
conditions. In vitro activity of an agent against a target organism,
suggests potential but does not predict efficacy in plant disease
control.
The assays of Formula S-100 demonstrated its in
vitro activity at 22 hours against multiple isolates of four
important bacterial pathogens of important crops. Even at very low
concentrations, Formula S-100 was highly active against Cmn, the
causal agent of Goss's wilt and blight of maize, Cmm, the causal
agent of bacterial canker of tomato and Cmi, the causal agent of
bacterial wilt of alfalfa, as shown in FIG. 18 and FIG. 19. Except
for one of the two strains of Cmi (which may be an atypical strain),
these pathogens did not survive at a concentration of 61 ppm
(MIC=1:16384), which is impressive. Previously, Cmn was tested
against S-102, and in those tests, the pathogen did not survive a
concentration of 980 ppm (or 0.098%) (MIC=1:1024).
Formula
S-100 demonstrated a reduced activity at 22 hours against Cff, the
agent of bacterial wilt of bean (MIC=1:64 for one isolate and
MIC=1:128 for the other). These results for Cff were similar to the
results for S-102 vs. Cff.
The activity of Formula S-101 at
two hours was tested for one of the two replicates for two strains of
Cmn, one strain of Cmm, one strain of Cmi, and the Cff strain, as
shown in FIG. 20. The results at two hours, limited as the result was
by assaying only one replicate of fewer strains, were similar to the
results at 22 hours, but the additional incubation time did appear to
allow lower concentrations of Formula S-100 to be more effective
relative to the two-hour incubation.
Based on these promising
results, areas for further study might include a testing activity of
Formula S-101 or S-102 (or both) at several concentrations in a
greenhouse and field-grown plants to evaluate efficacy and
phytotoxicity in planta (in plants), selection of a delivery method
of agent and pathogen, and time sequence studies to assess death rate
of bacterial pathogens when the agent is applied prior to or after
plant inoculation.
FIG. 18 is a table 1800 of a second screen
of pathogens vs. dilution of Formula S-101, in accordance with some
embodiments. Further, the second screen may include results at 96
hours after treatment for 22 hours.
FIG. 19 is a table 1900
of the second screen of pathogens vs. dilution of Formula S-101, in
accordance with some embodiments. Further, the second screen may
include results at 96 hours after treatment for 22 hours.
FIG.
20 is a table 2000 of a subset of the second screen of pathogens vs.
dilutions of Formula S-101, in accordance with some embodiments.
Further, the second screen of the subset may include results at 96
hours after treatment for either 2 or 22 hours.
FIG. 21 is a
table 2100 of therapeutic options for fungal lung infections.
FIG.
22 is a table 2200 of antifungal treatment options.
FIG. 23
is a flow diagram of a method 2300 of facilitating producing the
medicine composition for treating diseases using the medicine
composition, in accordance with some embodiments. Further, the
medicine composition may include the carbanions. Further, the method
2300 may include four stages 2302-2308. Further, the four stages
2302-2308 may include a mining stage 2302, a mixture stage 2304, a
production stage 2306, and a treatment stage 2308.
FIG. 24 is
a flow diagram of the method 2300 of facilitating producing the
medicine composition for treating the diseases using the medicine
composition, in accordance with some embodiments. Further, at 2402,
the mining stage 2302 may include gathering plants. Further, at 2404,
the mining stage 2302 may include extracting carbon. Further, at
2406, the mixture stage 2304 may include gathering the extracted
carbon. Further, at 2408, the mixture stage 2304 may include adding
additional ingredients to the carbon. Further, at 2410, the mixture
stage 2304 may include mixing until the ingredients and carbon are
well combined. Further, at 2412, the production stage 2306 may
include placing the mixture in a container that may be able to
sustain heat. Further, at 2414, the production stage 2306 may include
applying the heat to create an exothermic reaction to the mixture.
Further, at 2416, the production stage 2306 may include forming of
the carbanions within the mixture. Further, at 2418, the treatment
stage 2308 may include inserting one ounce of water into a nebulizer.
Further, at 2420, the treatment stage 2308 may include inserting
three droplets of the product comprising the carbanion into the
nebulizer. Further, at 2422, the treatment stage 2308 may include
using the nebulizer and inhaling until the nebulizer is empty.
FIG.
25 is a flow diagram of the mining stage 2302 of the method 2300, in
accordance with some embodiments.
FIG. 26 is a flow diagram
of the mixture stage 2304 of the method 2300, in accordance with some
embodiments.
FIG. 27 is a flow diagram of the production
stage 2306 of the method 2300, in accordance with some embodiments.
FIG. 28 is a flow diagram of the treatment stage 2308 of the
method 2300, in accordance with some embodiments.
FIG. 29 is
a table 2900 of compositional elements of the medicine composition,
in accordance with some embodiments.
FIG. 30 is a chart 3000
of the lab results of the medicine composition, in accordance with
some embodiments.
FIG. 31 is a table 3100 of compositional
elements of the medicine composition, in accordance with some
embodiments.
Although the present disclosure has been
explained in relation to its preferred embodiment, it is to be
understood that many other possible modifications and variations can
be made without departing from the spirit and scope of the
disclosure.
Are you from China 100+ daily visitors? No Calls or Emails or I will block the country. WhatsApp 336-306-0193
ebook-femtotechnology-agriculture-may-2021-uspto-10994999.com/
ebook-femtotechnology-medicines-may-2021-uspto-11000541.com/
ebook-femtotechnology-cleaning-jan-2022-uspto-11225632.com
www.americas-epa-approved-pesticides-farming-land.com
www.african-asian-agriculture.com
www.agri-safe.com
www.animal-feed-dry-matter.com
www.atomic-agriculture.com
www.atomic-medicine.com
www.bio-logicals.com
www.basis-of-technology.com
www.bio-logicals.com
www.biobased.us
www.biopesticides.us
www.biorationals.com
www.carbon-atom-mining.com
www.biobased.us
www.clavibacter-michiganensis.com
www.epa-25b.com
www.femto-agriculture.com
www.femtoag.com
www.femto-cides.com
www.femto-clean.com
www.femto-cleaning.com
www.femto-energy.com
www.femto-medical.com
www.femto-technology.com
www.femtoag.com
www.femtoagriculture.com
www.femtocare.com
www.femtocides.com
www.femtophrama.com
www.femtotech.us
www.femtotechnology-cides.com
www.femtotechnology-medicine.com
www.femtotechnology-picotechnology-nanotechnology-microntechnology.com
www.femto-sustainability.com
www.femtotechnology.us
www.femto-technology.com
www.made-in-america.us
www.biologicals-to-atoms.com
www.molecules-to-atoms.com
www.morocco-agriculture.com
www.nomore-acm.com
www.nutures-nature.com
www.organo-phosphates.com
www.out-of-the-box.com
www.pico-medicine.com
www.pico-pesticides.com
www.pico-products.com
www.pico-technology.us
www.picoag.com
www.picocides.com
www.picocleaning.com
www.picosoap.com
www.picotech.us
www.trans-location.com
www.whra.com
Wonders-of-Plant-Growth.html
www.biobased.us/co2explained.html
Atoms%20of%20Elements%20for%20Fertilizer